Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.
LONG TERM BENEFITS OF ORAL AGENTS
Therapy of Type 2 Diabetes Mellitus: UPDATE
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Oral Hypoglycemic Drugs
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Practical Implementation as a Discussion with the Patient, Part 2 Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 1 of 5.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Medical Professionals
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Therapy of Type 2 Diabetes Mellitus: UPDATE
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.
SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
DH206: Pharmacology Chapter 21: Diabetes Mellitus Lisa Mayo, RDH, BSDH.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
Pioglitazone  ADVANTAGES-  Improves insulin resistance (fat/muscle), decreases insulin conc., improves endothelial dysfunction, dysfibrinolysis, BP,
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
CV Risk of SU and Insulin
Type 2 diabetes.
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.
Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.
Macrovascular Complications Microvascular Complications
Choice of Therapy MYTH: “Most Patients with ‘T2DM’ will eventually
Strategies for the Practical Management of Type 2 Diabetes
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
IRIS Trial Insulin Resistance Intervention after Stroke.
Pathophysiology and drug targets.
Presentation transcript:

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor of Medicine, U of Pa An Aggressive Pathophysiologic Approach to Therapy of Type 2 Diabetes in Cardiometabolic Patients: Looking at Diabetes Medications with a Cardiologists Eye Part 8

Pioglitazone  ADVANTAGES-  Improves insulin resistance (fat/muscle), decreases insulin conc., improves endothelial dysfunction, dysfibrinolysis, BP, decreased microalbumin, improved beta-cell function, treats PCOS and steatohepatitis Lipids (GLIA study) Advantage to pio - decrease TG, decreased # of buoyant LDL particles, decrease non-HDL chol. May use in renal insufficiency  No hypoglycemia used alone or with metformin, incretin mimetics  Potential to delay or prevent DM and progression; lower secondary failure rate than SU/met  Pio decreased prospective composite endpoint (MI,CVA, death) 16% in PROactive trial (Can’t assume class effect), dec. risk second MI/ ACS, decreased risk second stroke 47%

Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes,Treating Defronzo’s Octet: Match Patient Characteristics to Drug Characteristics: PIOGLITAZONE improves 5 of 8 MOAs 5. Gut CHO Absorption: Incretin, Pramlintide, Glucosidase inh. Peripheral glucose uptake Pancreatic insulin Secretion: Incretin, ranolazine 2.Pancreatic glucagon Secretion- Incretin HYPERGLYCEMIA 6.Fat- TZD, metformin 7.Brain- TZD,INCRETIN, bromocryptine 8.Kidney- SGLT2 3. Muscle- TZD, Incretin 4.Liver Hepatic glucose production: Metformin, incretin De

Pioglitazone in Dysmetabolic Syndrome, Prediabetes, Type 2 Diabetes  Safety  No liver toxicity  Increased distal fractures in women  Edema-renal sodium and total body water retention - can be prevented/minimized (patient selection, NAS diet) - treated with spironolactone, amilioride, triamterene  Weight gain not an obligatory side effect- studies- portion control/ education freq.  Bone loss in women = risk/benefit evaluation for each patient  CHF not a cardiac issue except more susceptible with diastolic dysfunction –function of renal sodium and total body water retention -Can be prevented/reduced- low salt diet/ patient selection; ranolazine

© 2000 educateMD.com University of Pennsylvania School of Medicine Wang CH, et al. Glitazones and Heart Failure. Circulation. 2003;107: Reprinted with permission